Lotteries and Tobacco Money: Basic Research Bonanza?

Boosted by revenue from lotteries and tobacco company settlements, state-financed basic research in the life sciences is soaring. The goal of such funding is usually to create wealth by attracting federal and private money. But this strategy raises difficult questions about how best to measure research outcomes, policy specialists say. At least 17 states have directed tobacco settlement money into research and all but three of them are focusing on fundamental studies rather than direct commerc

Written bySteve Bunk
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

At least 17 states have directed tobacco settlement money into research and all but three of them are focusing on fundamental studies rather than direct commercialization, observes Walter H. Plosila, vice president of public technology management at the nonprofit Battelle Memorial Institute, a technology developer in Columbus, Ohio. For example, Michigan has a $1 billion life sciences research initiative, Florida is spending $1.7 billion on biomedical research, and California has put into place a competitive program to fund its universities in a variety of research fields. However, Plosila warns, "The federal government is hardly a model for trying to gauge and measure the impact of these programs."

States now must devise ways to assess "how much money makes sense," acknowledges J. David Roessner, associate director of the science and technology policy program at consultants SRI International of Menlo Park, Calif. "States are making attempts to collect and report performance and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies